The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Open accessAbstract
BACKGROUND: Invasive fungal infections are an important cause of morbidity and mortality after allogeneic hematopoietic stem-cell transplantation. METHODS: In an international, randomized, double-blind trial, we compared oral posaconazole with oral fluconazole for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy. The primary end point was the incidence of proven or probable invasive fungal infections from randomization to day 112 of the fixed treatment period of the study. RESULTS: Of a total of 600 patients, 301 were assigned to posaconazole and 299 to fluconazole. At the end of the fixed 112-day treatment period, posaconazole was found to be as effective as fluconazole in preventing all invasive fungal infections (incidence, 5.3% and 9.0%, respectively; odds ratio, 0.56; 95 percent confidence interval [CI], 0.30 to 1.07; P=0.07) and was superior to fluconazole in preventing proven or probable invasive aspergillosis (2.3% vs. 7.0%; odds ratio, 0.31; 95% CI, 0.13 to 0.75; P=0.006). While patients were receiving study medications (exposure period), in the posaconazole group, as compared with the fluconazole group, there were fewer breakthrough invasive fungal infections (2.4% vs. 7.6%, P=0.004), particularly invasive aspergillosis (1.0% vs. 5.9%, P=0.001). Overall mortality was similar in the two groups, but the number of deaths from invasive fungal infections was lower in the posaconazole group (1%, vs. 4% in the fluconazole group; P=0.046). The incidence of treatment-related adverse events was similar in the two groups (36% in the posaconazole group and 38% in the fluconazole group), and the rates of treatment-related serious adverse events were 13% and 10%, respectively. CONCLUSIONS: Posaconazole was similar to fluconazole for prophylaxis against fungal infections among patients with GVHD. It was superior in preventing invasive aspergillosis and reducing the rate of deaths related to fungal infections. (ClinicalTrials.gov number, NCT00034645 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
(2016) · Diagnostic Pathology: Hospital Autopsy · doi:10.1016/b978-0-323-37676-1.50073-x · Cited by 1,335
Ferrara, J. L. M., & Deeg, H. J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103073241005 · Cited by 1,219
Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,174
Self-citationMarr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
Slavin, M. A., Osborne, B., Adams, R., Levenstein, M. J., Schoch, H. G., Feldman, A. R., Meyers, J. D., & Bowden, R. A. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1545 · Cited by 820
Walsh, T. J., Raad, I., Patterson, T. F., Chandrasekar, P., Donowitz, G. R., Graybill, R., Greene, R. E., Hachem, R., Hadley, S., Herbrecht, R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/508774 · Cited by 752
Self-citationvan Burik, J.-A. H., Ratanatharathorn, V., Stepan, D. E., Miller, C. B., Lipton, J. H., Vesole, D. H., Bunin, N., Wall, D. A., Hiemenz, J. W., Satoi, Y., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/422312 · Cited by 744
Self-citationWald, A., Leisenring, W., van Burik, J., & Bowden, R. A. (1997) · The Journal of Infectious Diseases · doi:10.1086/516480 · Cited by 742
Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 Cases
van Burik, J.-A. H., Hare, R. S., Solomon, H. F., Corrado, M. L., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/500212 · Cited by 615
Espinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2950-2956.1998 · Cited by 576
Marr, K. A., Seidel, K., Slavin, M. A., Bowden, R. A., Schoch, H. G., Flowers, M. E. D., Corey, L., & Boeckh, M. (2000) · Blood · doi:10.1182/blood.v96.6.2055 · Cited by 511
Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-06 · Cited by 491
Fukuda, T., Boeckh, M., Carter, R. A., Sandmaier, B. M., Maris, M. B., Maloney, D. G., Martin, P. J., Storb, R. F., & Marr, K. A. (2003) · Blood · doi:10.1182/blood-2003-02-0456 · Cited by 465
Marr, K. A., Crippa, F., Leisenring, W., Hoyle, M., Boeckh, M., Balajee, S. A., Nichols, W. G., Musher, B., & Corey, L. (2004) · Blood · doi:10.1182/blood-2003-08-2644 · Cited by 442
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1032-1037.2002 · Cited by 404
Winston, D. J., Maziarz, R. T., Chandrasekar, P. H., Lazarus, H. M., Goldman, M., Blumer, J. L., Leitz, G. J., & Territo, M. C. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-9-200305060-00006 · Cited by 389
Self-citationRaad, I. I., Hachem, R. Y., Herbrecht, R., Graybill, J. R., Hare, R., Corcoran, G., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/503425 · Cited by 302
Systemic Antifungal Agents: Drug Interactions of Clinical Significance
Albengres Herv??, E., Lou??, L., & Tillement, J.-P. (1998) · Drug Safety · doi:10.2165/00002018-199818020-00001 · Cited by 280
Ullmann, A. J., Cornely, O. A., Burchardt, A., Hachem, R., Kontoyiannis, D. P., Töpelt, K., Courtney, R., Wexler, D., Krishna, G., Martinho, M., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.658-666.2006 · Cited by 273
Self-citationIncidence and risk factors for invasive fungal infections in allogeneic BMT recipients
Jantunen, E., Ruutu, P., Niskanen, L., Volin, L., Parkkali, T., Koukila-Kähkölä, P., & Ruutu, T. (1997) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1700737 · Cited by 251
Ribaud, P., Chastang, C., Latgé, J., Baffroy‐Lafitte, L., Parquet, N., Espéton, A. D. H., Sélimi, F., Rocha, V., Derouin, F., Socié, G., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/515116 · Cited by 236
Fungal infections in bone marrow transplant patients.
Meyers, J. D. (1990) · PubMed · Cited by 224
Martino, R., Subirá, M., Rovira, M., Solano, C., Vázquez, L., Sanz, G. F., Urbano‐Ispizua, A., Brunet, S., De la Cámara, R., & (GETH), F. T. A. I. C. S. O. T. G. E. D. T. H. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03259.x · Cited by 221
Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents
Barry, A. L., Pfaller, M. A., Brown, S. D., Espinel-Ingroff, A., Ghannoum, M. A., Knapp, C., Rennie, R. P., Rex, J. H., & Rinaldi, M. G. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.9.3457-3459.2000 · Cited by 211
Non-Candida fungal infections after bone marrow transplantation: Risk factors and outcome
Morrison, V. A., Haake, R. J., & Weisdorf, D. J. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90088-4 · Cited by 211
Morgenstern, G. R., Prentice, A. G., Grant Prentice, H., Ropner, J. E., Schey, S. A., Warnock, D. W., & on behalf of the U.K. Multicentre Antifungal Prophylaxis Study Group (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01465.x · Cited by 201
Grow, W., Moreb, J., Roque, D., Manion, K., Leather, H., Reddy, V, Khan, S., Finiewicz, K., Nguyen, H., Clancy, C., et al. (2002) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703332 · Cited by 192
Self-citationSaugier-Véber, P., Devergié, A., Sulahian, A., Ribaud, P., Traoré, F., Espérou, H., Gluckman, É., & Derouin, F. (1993) · PubMed · Cited by 112
Aspergillus infections in bone marrow transplant recipients.
Wingard, J. R., Beals, S., Santos, G. W., Merz, W. G., & Saral, R. (1987) · PubMed · Cited by 108
Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation
Thursky, K., Byrnes, G. B., Grigg, A., Szer, J., & Slavin, M. A. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704543 · Cited by 94
Shen, J. X., Krishna, G., & Hayes, R. N. (2006) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2006.06.011 · Cited by 84
Espinel-Ingroff, A., Bartlett, M., Chaturvedi, V., Ghannoum, M., Hazen, K. C., Pfaller, M. A., Rinaldi, M., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1828-1835.2001 · Cited by 83
Detection of galactomannan antigenemia by enzyme immunoassay in experimental invasive aspergillosis
de Repentigny, L., Boushira, M., Ste-Marie, L., & Bosisio, G. (1987) · Journal of Clinical Microbiology · doi:10.1128/jcm.25.5.863-867.1987 · Cited by 58
Cited by
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Metadata
- Authors
- Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., Pedicone, L., Patino, H., & Durrant, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-01-25
- Volume
- 356
- Issue
- 4
- Pages
- 335-347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1988385266
- Cited by
- 1,345
- References
- 37
- FWCI
- 81.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.